Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754409 | 0.78 | DPP4 (0.61) | DPP4ADORA1ADORA3ADORA2APIK3CG | |
| SCHEMBL5752615 | 0.73 | CYP1A2 (0.44) | HRH2HRH3ALOX5PIK3CGPIK3CA | |
| SCHEMBL3618779 | 0.73 | ADORA2A (0.59) | DPP4ADORA1HRH2HRH3ADORA2A | |
| SCHEMBL3368583 | 0.72 | DPP4 (1.00) | DPP4ADORA1ADORA3ADORA2ACYP3A4 | |
| SCHEMBL25823075 | 0.71 | TDP1 (0.51) | ADORA1ADORA3ADORA2AKMT2AS1PR1 | |
| SCHEMBL12291102 | 0.71 | HTR2C (0.53) | CYP1A2CYP3A4CYP2C9CYP2B6CYP2D6 | |
| SCHEMBL25823052 | 0.71 | S1PR1 (0.49) | ADORA1ADORA3ADORA2AKMT2AS1PR1 | |
| SCHEMBL28221101 | 0.71 | L3MBTL1 (0.57) | ADORA1ADORA3ADORA2AS1PR1 | |
| SCHEMBL3369169 | 0.70 | ADORA1 (0.71) | DPP4ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5923973 | 0.70 | DPP4 (0.56) | DPP4ADORA1ADORA3ADORA2APIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | NEUROGEN CORPORATION (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | TRPV1, GPR17, TRPV2 | DPP4 1375/4885ADORA1 554/4885ADORA3 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.